Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Vanguard Information Technology ETF
VGT
$139B
| $45.2M | 0.02% |
518,368
-7,192
| -1% | -$662K |
|
252
Delek US
DK
$4.15B
| $44.9M | 0.02% |
995,711
-48,982
| -5% | -$1.75M |
|
253
KLA
KLAC
$236B
| $44.8M | 0.02% |
304,090
+13,160
| +5% | +$1.93M |
|
254
T. Rowe Price
TROW
$25.6B
| $44M | 0.01% |
488,348
-1,117,471
| -70% | -$108M |
|
255
Murphy Oil
MUR
$5.48B
| $43.7M | 0.01% |
1,060,314
+27,107
| +3% | +$918K |
|
256
Abercrombie & Fitch
ANF
$4.45B
| $43.7M | 0.01% |
478,149
-11,305
| -2% | -$1.1M |
|
257
Baker Hughes
BKR
$59.5B
| $43.4M | 0.01% |
711,469
+40,441
| +6% | +$2.34M |
|
|
BELFB
258
Bel Fuse Inc Class B
BELFB
$3.6B
| $42.7M | 0.01% |
215,648
-35,960
| -14% | -$7.51M |
|
259
Ferrovial N.V. Ordinary Shares
FER
$46.9B
| $42.1M | 0.01% |
653,980
+56,446
| +9% | +$3.8M |
|
260
O'Reilly Automotive
ORLY
$72.4B
| $41.5M | 0.01% |
449,380
-176,780
| -28% | -$16.6M |
|
261
FormFactor
FORM
$8.21B
| $41.3M | 0.01% |
425,994
-10,051
| -2% | -$865K |
|
262
Palo Alto Networks
PANW
$265B
| $41.1M | 0.01% |
256,661
+249,534
| +3,501% | +$41.9M |
|
263
Winmark
WINA
$1.19B
| $40.8M | 0.01% |
95,370
-9,317
| -9% | -$4.11M |
|
264
Granite Construction
GVA
$5.03B
| $40.6M | 0.01% |
338,364
-8,612
| -2% | -$1.07M |
|
265
Zurn Elkay Water Solutions
ZWS
$8.31B
| $39.9M | 0.01% |
889,432
-92,247
| -9% | -$4.41M |
|
266
Kennametal
KMT
$2.54B
| $38.9M | 0.01% |
1,075,576
-116,695
| -10% | -$4.25M |
|
267
American Eagle Outfitters
AEO
$2.9B
| $37.1M | 0.01% |
2,224,442
-153,680
| -6% | -$3.45M |
|
268
Kaiser Aluminum
KALU
$2.61B
| $36.7M | 0.01% |
304,507
+147,429
| +94% | +$18.7M |
|
269
Glacier Bancorp
GBCI
$6.38B
| $35.7M | 0.01% |
799,694
-33,198
| -4% | -$1.57M |
|
270
Invesco
IVZ
$13B
| $35.5M | 0.01% |
1,461,487
-4,047,257
| -73% | -$106M |
|
271
Boot Barn
BOOT
$4.68B
| $35.2M | 0.01% |
240,439
-2,308
| -1% | -$418K |
|
272
Viridian Therapeutics
VRDN
$2.2B
| $34.6M | 0.01% |
1,768,295
-11,989
| -0.7% | -$356K |
|
273
Resideo Technologies
REZI
$5.26B
| $34.6M | 0.01% |
1,025,835
-46,496
| -4% | -$1.66M |
|
274
Honeywell
HON
$76.7B
| $34.1M | 0.01% |
150,757
+4,219
| +3% | +$964K |
|
275
Bio-Rad Laboratories Class A
BIO
$8.74B
| $33.1M | 0.01% |
118,683
-12,411
| -9% | -$3.57M |
|
Similar funds
Ken Fisher's Q1 2026 Portfolio in Review
As of Q1 2026, Ken Fisher held 1,133 positions worth $295B, up 0.65% from $293B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Ken Fisher's Q1 2026 filing shows 116 new, 416 increased, 461 reduced and 117 closed positions. Its largest new stake was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M. The largest sale was Abbott, an estimated $1.21B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 25% a quarter earlier, followed by Financials and Industrials.
- Ken Fisher's largest Q1 2026 buy was Portfolio Building Block World Pharma and Biotech Index ETF: 28,040,859 shares worth $717M.
- Ken Fisher added most to AbbVie in Q1 2026, an estimated $1.88B increase.
- Ken Fisher's biggest Q1 2026 reduction was Abbott, cutting an estimated $1.21B.
- Ken Fisher fully exited Trip.com Group in Q1 2026, selling an estimated $175M.
- Ken Fisher's ten largest holdings make up 33% of its $295B portfolio in Q1 2026.
- Ken Fisher opened 116 new positions and closed 117 in Q1 2026.
- Ken Fisher's portfolio value rose 0.65% quarter-over-quarter to $295B.
Based on Fisher Asset Management's 13F filing for Q1 2026, filed 5 May 2026.